Spots Global Cancer Trial Database for Efficacy and Safety of Adjuvant Pemetrexed Plus Cisplatin for Adenocarcinoma of Lung
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Efficacy and Safety of Adjuvant Pemetrexed Plus Cisplatin for Adenocarcinoma of Lung
Official Title: Efficacy and Safety of Pemetrexed Plus Cisplatin as Combination Chemotherapy for Post-operative Adenocarcinoma : Multi-center, Single Arm, Open-label, Phase Ⅱ Trial
Study ID: NCT02498860
Study Description
Brief Summary: Two-Year Disease Free Survival Rate of Stage IB\~IIIA adenocarcinoma after Adjuvant Chemotherapy with Pemetrexed and Cisplatin will be assessed. A total of 106 patients will be recruited for 12 months, and followed for two years, thus the duration of study will be 36 months.
Detailed Description: Primary endpoint : 2 year disease free survival Secondary endpoints: Overall survival, Frequency and severity of adverse events
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Chonnam National University Hwasun Hospital, Hwasun, Jeonnam, Korea, Republic of
Kyungpook National University Medical Center, Daegu, Kyungpook, Korea, Republic of
Chungnam National University Hospital, Daejeon, , Korea, Republic of
Pusan National University Hospital, Pusan, , Korea, Republic of
Kosin University Gospel Hospital, Pusan, , Korea, Republic of
Korea university Guro hospital, Seoul, , Korea, Republic of
Severance hospital, Seoul, , Korea, Republic of
Contact Details
Name: Young-Chul Kim, MD, PhD
Affiliation: Chonnam National University Hospital
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
